About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our main scientific interest is to understand, from a multidisciplinary and translational approach, the molecular and cellular processes leading to renal dysfunction in several kidney pathologies. Specifically, our research lines are
We are experts on the following areas:
To sum up, our research main objective is to combine –omic data from cellular and animal models with patients’ data to identify novel biomarkers and possible treatments for several renal diseases.
IP: Joan Morote Robles Collaborators: Fernando Lozano Palacio, Inés de Torres Ramirez, Enric Trilla Herrera, Olga Méndez Fernández, Ana Celma Domènech, Mercè Cuadras Solé, Carlos Serrano Burgos, Albert Carrión Puig, Enric Miret Alomar, Maria Eugenia Semidey Raven, Carles Xavier Raventós Busquets, Rercerca biomèdica en urologia , Jacques Planas Morin, Richard Mast, Anna Santamaria Margalef Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00858 Duration: 01/01/2022 - 30/06/2025
IP: Gema Ariceta Iraola Collaborators: Hector Rios Duro, Mónica Durán Fernández, Gloria Mª Fraga Rodriguez, Julieta Torchia, Julieta Torchia Funding agency: Instituto de Salud Carlos III Funding: 202070 Reference: PI22/01946 Duration: 01/01/2023 - 31/12/2025
IP: Gerard Cantero Recasens Collaborators: Papel del ClC-5 en la fibrosis renal. Identificación de posibles biomarcadores y dianas terapéuticas para la progresión de la e, Hector Rios Duro, Mónica Durán Fernández, Gloria Mª Fraga Rodriguez, Julieta Torchia, Julieta Torchia, Andrea Casal Pardo Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI22/00741 Duration: 01/01/2023 - 31/12/2025
IP: Maria Antonia Emilia Meneghini Collaborators: Lluis Castells Fusté, Joana Sellarés Roig, Jesús Quintero Bernabeu, Eva Maria Revilla Lopez, Marina Muñoz López, Meritxell Boada Perez, Laura Donadeu Casassas, Mercedes López González Funding agency: Instituto de Salud Carlos III Funding: 111320 Reference: PI22/00749 Duration: 01/01/2023 - 31/12/2025
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The aim of the project is to establish kidney organoids derived from patients with familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, which will be essential tools for studying the disease and testing new treatments.
The work identifies variants in genes such as NFU1 that, combined with the disease-causing mutation, can accelerate kidney deterioration.
